fls.txt
We evaluated all positive and negative evidence in concluding it was appropriate to release the majority of the valuation allowance against U.S. net deferred tax assets during fiscal year 2018.


item1.txt
This portion of the adjustment is derived from the new requirement to recognize the cost to obtain certain transactions over time under ASC 340-40, while historically this expense has been recognized at a point in time.
The Company recognizes revenue as work progresses based on a percentage of actual labor hours incurred on the project to-date and total estimated labor hours expected to be incurred on the project.
The accompanying notes are an integral part of these unaudited consolidated financial statements.
On July 1, 2019, the Company completed the Disposition for $675.0 million, subject to adjustments for working capital and other items.
ASU 2019-05 amends ASU 2016-13 to allow companies to irrevocably elect, upon adoption of ASU 2016-13, the fair value option on financial instruments that were previously recorded at amortized cost and are within the scope of ASC 326-20 if the instruments are eligible for the fair value option under ASC 825-10.
The accompanying Consolidated Balance Sheet as of September 30, 2018 was derived from the audited annual consolidated financial statements as of the period then ended.
Except as provided in the Amendment, the incremental term loan was subject to the same terms and conditions as set forth in the existing credit agreement.
ASU 2019-05 amends ASU 2016-13 to allow companies to irrevocably elect, upon adoption of ASU 2016-13, the fair value option on financial instruments that were previously recorded at amortized cost and are within the scope of ASC 326-20 if the instruments are eligible for the fair value option under ASC 825-10.
This acquisition has expanded customer relationships and geographic reach within its growing sample management storage services business in the Brooks Life Sciences segment.
On October 4, 2017, the Company entered into a $200.0 million term loan with the lenders pursuant to the terms of a credit agreement.
At June 30, 2019 and September 30, 2018, the Company had cumulative capitalized direct costs of $9.1 million and $5.6 million, respectively, associated with the development of software for its internal use which are included within "Property, plant and equipment, net" in the accompanying unaudited Consolidated Balance Sheets.
Under the Amendment, the Company obtained an incremental term loan in an aggregate principal amount of $350.0 million.
Deferred commissions represent a direct and incremental cost of obtaining a contract.
Upon the adoption of ASC 606, the Company is no longer required to defer revenue in accordance with billing constraints defined in the contract with the customer.
The weighted average grant date fair value of restricted stock units granted during the nine months ended June 30, 2019 and 2018 was $30.47 and $33.31, respectively.
and Wells Fargo Securities, LLC (collectively, the “lenders”).
●Products, including sales of tool automation and automated cold sample management systems, atmospheric and vacuum robots, contamination control solutions, as well as consumables and spare parts.
Accounts receivable represent rights to consideration in exchange for products or services that have been transferred by the Company, when payment is unconditional and only the passage of time is required before payment is due.
 The Company allocated the purchase price of $5.2 million based on the fair value of the assets and liabilities acquired as of the acquisition date, which included $0.3 million of accounts receivable, $2.6 million of customer relationships, $2.7 million of goodwill and $0.7 million of assumed liabilities.


item2.txt
The Company expects to settle the other obligations from the sale including estimated closing costs of $13 million in the fourth quarter of fiscal 2019, and estimated taxes of $105 million in the second quarter of fiscal 2020.
During the three and nine months ended June 30, 2019, we have incurred $0.1 million in capital expenditures related to the construction of this facility.
As described above, the Company routinely invests certain amounts of its cash balance in marketable securities.
We reported an increase in contamination control solutions of $35.7 million, of which $15.1 million is attributable to six additional months of revenue for the acquisition of Tec-Sem, acquired on April 1, 2019, this was partially offset by declines in automation systems of $19.1 million and services of $1.2 million.
Partially offsetting these items were the uses of cash of $18.4 million related to the changes in our operating assets and liabilities.
The difference in reported revenue due to the adoption of the new revenue recognition standard was a net increase of $0.2 million and $0.8 million for the three and nine months ended June 30, 2019, respectively.
GENEWIZ provides gene sequencing and synthesis services for more than 4,000 institutional customers worldwide supported by their global network of laboratories spanning the United States, China, Japan, Germany and the United Kingdom.
The difference in reported gross margin due to the adoption of the new revenue recognition standard was a net decrease in gross profit of $0.6 million and $1.8 million during three and nine months ended June 30, 2019, respectively.
Gross margin increased in the Brooks Life Sciences segment by 3.7 percentage points and in the Brooks Semiconductor Solutions Group by 0.1 percentage points in the 2019 period over the 2018 period.


item3.txt
Such balances were approximately $123.4 million and $84.7 million, respectively, at June 30, 2019 and September 30, 2018, and related to the Euro, British Pound and a variety of Asian currencies.


item4.txt



part2.txt



